| - |
Imiquimod 3.75% |
Zyclara® |
For topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. |
Rapid Review Complete |
19th September 2013 |
 |
| 23041 |
Imlifidase |
Idefirix® |
For desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. |
NCPE Assessment Process Complete |
28th November 2024 |
|
| 25056 |
Inavolisib |
Itovebi® |
Inavolisib, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. |
Awaiting full HTA submission from Applicant |
6th October 2025 |
|
| 20051 |
Inclisiran |
Leqvio® |
For the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adult patients, as an adjunct to diet (a) in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or (b) alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. |
Assessment process complete |
23rd March 2022 |
|
| - |
Incobotulinum Toxin Type A |
Xeomin® |
For the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults. |
Rapid Review Complete |
6th March 2014 |
|
| - |
Indacaterol |
Onbrez® |
For the treatment of COPD. |
Rapid Review Complete |
15th January 2010 |
|
| 20023 |
Indacterol/glycopyrronium/mometasone furoate |
Enerzair® |
As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. |
Rapid Review Complete |
10th June 2020 |
|
| 20024 |
Indacterol/mometasone furoate |
Atectura® |
As maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists. |
Rapid Review Complete |
10th June 2020 |
|
| - |
Infliximab |
Inflectra® |
For the treatment of Rheumatoid Arthritis, Adult Crohn’s disease, Paediatric Crohn’s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis. |
Rapid Review Complete |
24th September 2013 |
|
| 26017 |
Infliximab induction phase of treatment in patients with rheumatoid arthritis |
Remsima SC® |
Infliximab (Remsima SC®) is indicated in combination with methotrexate, indicated in rheumatoid arthritis (RA) for the reduction of signs and symptoms as well as the improvement in physical function in: • Adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. • Adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs*. Reimbursement is sought for the infliximab 120mg solution for injection in pre-filled pen (PFP) (pack of four pens) for the induction phase of treatment in patients with RA. |
Rapid Review Complete |
24th April 2026 |
|
| 20012 |
Infliximab |
Remsima SC® |
In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. |
Rapid Review Complete |
24th March 2020 |
|
| 20042 |
Infliximab |
Remsima® SC |
For treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation. |
Rapid Review Complete |
15th October 2020 |
|
| 25022 |
Infliximab |
Remsima® |
Infliximab (Remsima®) is indicated for the treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. It is also indicated for treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy). |
Rapid Review Complete |
11th April 2025 |
|
| - |
Ingenol mebutate |
Picato® |
For cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults. |
Rapid Review Complete |
6th December 2012 |
|
| - |
Inhaled insulin |
Exubera® |
Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. |
Assessment process complete |
13th July 2006 |
|
| 19034 |
Inotersen |
Tegsedi® |
For the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR). |
Assessment process complete |
11th February 2022 |
|
| - |
Inotuzumab ozogamicin |
Besponsa® |
As monotherapy for the treatment of adults with relapsed or refractory (R/R) CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). |
Assessment process complete |
14th September 2018 |
|
| - |
Insulin aspart |
Fiasp® |
For the treatment of diabetes mellitus in adults. |
Rapid Review Complete |
14th June 2017 |
|
| - |
Insulin aspart |
NovoRapid® FlexTouch ® |
For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Rapid Review Complete |
28th August 2014 |
|
| - |
Insulin Degludec |
Tresiba® |
Treatment of diabetes mellitus |
Assessment process complete |
6th May 2015 |
|
| - |
Insulin degludec/liraglutide (IDegLira) |
Xultophy® |
For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control. |
Rapid Review Complete |
18th October 2016 |
|
| - |
Insulin Glargine |
Abasaglar® |
For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Rapid Review Complete |
12th October 2015 |
|
| - |
Insulin Glargine U300 |
Toujeo® |
for the treatment of diabetes mellitus in adults. |
Rapid Review Complete |
2nd July 2015 |
|
| - |
Ipilimumab |
Yervoy® |
For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy. |
Assessment process complete |
6th September 2011 |
|
| 24023 |
Iptacopan |
Fabhalta® |
Iptacopan is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. |
Rapid Review Complete |
16th July 2024 |
|
| - |
Iron (III) isomaltoside 1000 |
Diafer® |
For the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used. |
Rapid Review Complete |
20th November 2015 |
|
| - |
Iron (III) isomaltoside 1000 |
Monover® |
For the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. |
Rapid Review Complete |
20th November 2015 |
|
| - |
Iron isomaltoside 1000 |
MonoVer® |
For the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly. |
Rapid Review Complete |
2nd February 2011 |
|
| 23024 |
Isatuximab |
Sarclisa® |
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
Rapid Review Complete |
12th February 2026 |
|
| - |
Isavuconazole |
Cresemba® |
For the treatment of invasive aspergillosis |
Rapid Review Complete |
11th May 2016 |
|
| - |
Isavuconazole |
Cresemba® |
For the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. |
Rapid Review Complete |
11th May 2016 |
|
| 25016 |
Isavuconazole |
Cresemba® |
Isavuconazole (Cresemba®is indicated for patients from one year of age to < 18 years for the treatment of invasive aspergillosis, and mucormycosis in patients for whom amphotericin B is inappropriate. |
Rapid Review Complete |
25th March 2025 |
|
| 23031 |
Itopride Hydrochloride |
Progit® |
Treatment of gastrointestinal symptoms of functional dyspepsia caused by reduced gastrointestinal motility. |
Rapid Review Complete |
7th July 2023 |
|
| 20027 |
IUB™ Ballerine® |
IUB™ Ballerine® MIDI 15mm diameter SCU300B |
For intrauterine contraception for up to five years. |
Rapid Review Complete |
29th July 2020 |
|
| 20062 |
IUB™ Ballerine® |
IUB™ Ballerine® MIDI 15mm diameter SCU300B |
For intrauterine contraception for up to five years. |
Rapid Review Complete |
17th February 2021 |
|
| - |
Ivacaftor |
Kalydeco® |
For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation |
Assessment process complete |
1st February 2013 |
|
| - |
Ivacaftor |
Kalydeco® |
For the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. |
Assessment process complete |
12th October 2016 |
|
| - |
Ivacaftor |
Kalydeco® |
For the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene. |
Assessment process complete |
5th January 2017 |
|
| 22022 |
Ivacaftor/tezacaftor/elexacaftor |
Kaftrio® |
Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) in combination with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
NCPE Assessment Process Complete |
9th February 2023 |
|
| 23015 |
Ivosidenib |
Tibsovo® |
To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy. |
NCPE Assessment Process Complete |
16th December 2025 |
|
| 23016 |
Ivosidenib |
Tibsovo® |
For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy |
NCPE Assessment Process Complete |
7th March 2025 |
|
| - |
Ixazomib |
Ninlaro® |
In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
Assessment process complete |
18th December 2017 |
|
| - |
Ixekizumab |
Taltz® |
For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. |
Rapid Review Complete |
26th July 2016 |
|
| - |
Ixekizumab |
Taltz® |
For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies |
Rapid Review Complete |
20th November 2018 |
|
| 21046 |
Ketoconazole |
Ketoconazole HRA® |
For the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. |
Rapid Review Complete |
13th December 2021 |
|
| - |
Lacosamide |
Vimpat® |
As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age). |
Rapid Review Complete |
31st October 2017 |
|
| __ |
Lanadelumab |
Takhzyro® |
For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. |
Assessment process complete |
26th June 2020 |
|
| - |
Lapatinib |
Tyverb® |
For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer. |
Assessment process complete |
28th January 2008 |
|
| 19050 |
Larotrectinib |
Vitrakvi® |
For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21053 |
Latanoprost/Timolol |
Fixapost® |
In adults (including the elderly) for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‐blockers or prostaglandin analogues. |
Rapid Review Complete |
6th December 2021 |
|
